Physician profile
Ammar H Ali
NPI 1669797627
$1,276.66
in general payments reported to CMS, 2019-2025
9 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2023: $31.47 · 2024: $635 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.17 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $305.67 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $265.10 | 2023-2025 | Uzedy, Austedo Xr |
| Tms Neurohealth Centers INC. | $142.17 | 2025 | Tms Neurohealth Centers INC. |
| Janssen Pharmaceuticals, INC | $130.70 | 2024-2025 | Invega Sustenna |
| Indivior INC. | $116.27 | 2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $100.89 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $97.48 | 2024 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $63.26 | 2025 | Cobenfy |
| Neuronetics, INC. | $55.12 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.